Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 953 participants.
Also called NCT02104804
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 953 participants
- Sponsor
- Registry
-
NCT02104804
-
- Other papers using this trial's data
- Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02104804. Randomized; quadruple masking; primary purpose treatment. Start 2014-05-07 (actual); primary completion 2016-02-26 (actual). Results posted on 2017-10-02.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Saxagliptin 5mg
- Intervention (Drug)
- Placebo for Saxagliptin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct02104804- Content hash
fd5c745a097c4103cf36337a7c877e27f881a51bd8c2177069499e611af6cb51